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SUMMARY
Tripartite motif-containing protein 5a (TRIM5a) is
a cellular antiviral restriction factor that prevents
early events in retrovirus replication. The activity of
TRIM5a is thought to be limited to retroviruses as a
result of highly specific interactions with capsid lat-
tices. In contrast to this current understanding, we
show that both human and rhesus macaque TRIM5a
suppress replication of specific flaviviruses. Multiple
viruses in the tick-borne encephalitis complex are
sensitive to TRIM5a-dependent restriction, but mos-
quito-borne flaviviruses, including yellow fever,
dengue, and Zika viruses, are resistant. TRIM5a sup-
presses replication by binding to the viral protease
NS2B/3 to promote its K48-linked ubiquitination
and proteasomal degradation. Importantly, TRIM5a
contributes to the antiviral function of IFN-I against
sensitive flaviviruses in human cells. Thus, TRIM5a
possesses remarkable plasticity in the recognition
of diverse virus families, with the potential to influ-
ence human susceptibility to emerging flaviviruses
of global concern.
INTRODUCTION
Flaviviruses (family Flaviviridae) include 53 recognized virus spe-
cies, of which 40 are known to cause disease in humans, with
over 40% of the world’s population at risk of flavivirus infection
annually (Brady et al., 2012). These viruses have a high potential
for emergence into human populations, as witnessed historically
through global emergence of dengue virus (DENV), West Nile vi-
rus (WNV), and Zika virus (ZIKV). Additional (re)emerging viruses
of considerable medical importance include yellow fever virus
(YFV), Japanese encephalitis virus (JEV), and members of the
tick-borne encephalitis virus (TBEV) serogroup. Flaviviruses
share in common a positive-sense single-stranded RNA (ssRNA)
genome encoding a single polyprotein that is cleaved by host cell
signalases (Zhang et al., 2016) and the viral protease to generate
three structural (capsid [C], pre-membrane [M], and envelope [E])
and seven nonstructural (NS) proteins (NS1, NS2A, NS2B, NS3,
NS4A, NS4B, and NS5) (Lindenbach et al., 2007). Two of the
NS proteins have enzymatic activity; the NS3 protein encodes
the viral RNA helicase and together with its co-factor NS2B
(NS2B/3) functions as the viral protease, whereas NS5 pos-
sesses both methyltransferase (MTase) and RNA-dependent
RNA polymerase (RdRP) activities.
The repeated emergence of flaviviruses as human pathogens
is in part due to the fact that they are arthropod-borne, trans-
mitted by mosquitoes and ticks. In addition, the zoonotic reser-
voir species supporting virus replication in nature are highly
diverse. For example, small mammals, particularly rodents, are
thought critical for the maintenance of transmission cycles of
TBEV and related viruses. In contrast, WNV utilizes birds,
whereas DENV, ZIKV, and YFV evolved in non-human primates
before at least DENV and ZIKV established urban transmission
cycles maintained exclusively through human infections (Vasila-
kis and Weaver, 2017). The ability of a virus to avoid or evade
host antiviral responses is essential to establish replication and
transmission (Versteeg and Garcı´a-Sastre, 2010). However, it
is not fully understood how evolution in different reservoir
hosts to avoid innate immunity has shaped replication and path-
ogenesis of different flaviviruses following infection of humans.
Host-specific interactions with the interferon (IFN) response
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Figure 1. Stable Expression of TRIM5a in HEK293 Cells Restricts Replication of Specific Flaviviruses
(A) HEK293 cells stably overexpressing human (h) or rhesus (rh) TRIM5a-HA, hTRIM22-HA, or empty vector (control) were infected with tick-borne encephalitis
virus (TBEV), Kyasanur Forest disease virus (KFDV), Langat virus (LGTV), Powassan virus (POWV), West Nile virus (WNV), dengue virus (DENV-2), Zika virus
(ZIKV), or yellow fever virus (YFV) with a multiplicity of infection (MOI) of 0.001 (except YFV at MOI 0.1). Infectious virus release was determined in supernatants by
plaque assay. All data are from 3 independent experiments performed in triplicate (mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; n.s., not
significant, by Mann-Whitney). Grey dotted line indicates limit of detection.
(legend continued on next page)
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have been demonstrated for DENV and ZIKV that can only antag-
onize IFN-dependent signaling in the context of primate hosts
(Best, 2017; Stabell et al., 2018). However, the IFN-stimulated
genes (IGSs) that might also contribute to host-specific restric-
tion of flaviviruses are not well characterized.
Tripartite motif-containing proteins (TRIMs) are strong candi-
dates for mediating host-specific restriction of virus replication
in the context of an IFN response. Approximately 100 tripartite
TRIMs exist in the human genome (Han et al., 2011), many of
which are ISGs with functions as direct antiviral restriction fac-
tors or as modulators of the cellular response to infection (Rajs-
baum et al., 2014). The most characterized primate TRIM is
TRIM5a, which functions as a cellular antiviral restriction factor
with exquisite specificity, thought to restrict only retroviruses
through complex interactions with the capsid lattice structure
that accelerates uncoating of the viral nucleic acid and also
blocks reverse transcription (Ganser-Pornillos et al., 2011;
Stremlau et al., 2006; Wu et al., 2013). The significant influence
of TRIM5a is exemplified by the observations that its antiviral
activity drives lentivirus evolution (Wu et al., 2013) and limits
cross-primate species transmission (Hatziioannou et al., 2006).
Importantly, the relative ability of TRIM5a to bind retrovirus
capsid lattices directly impacts primate species susceptibility
to infection. For example, TRIM5a from Old World monkeys,
such as rhesus macaques (rhTRIM5a), exerts potent antiviral ac-
tivity against HIV-1 to confer host resistance. In contrast, human
TRIM5a (hTRIM5a) only weakly interacts with HIV-1 capsid lat-
tices, and this reduced efficacymay promote HIV-1 transmission
and disease progression (Merindol and Berthoux, 2015). The
antiviral specificity of TRIM5a has evolved rapidly in the past
30 million years of primate evolution, with particularly strong sig-
natures of positive selection over the last 4–5 million years (Kai-
ser et al., 2007; Sawyer et al., 2005). Evolutionary studies sup-
port the conclusion that TRIM5a positive selection throughout
primate evolution is driven at the interaction interface between
TRIM5a and retrovirus capsids and, thus, reinforce the paradigm
that the antiviral activity of TRIM5a and its role in host resistance
is specific to the retroviruses (McCarthy et al., 2015).
Given the extensive evolution of multiple medically important
flaviviruses with primate species, we examined the antiviral
capacity of both rhTRIM5a and hTRIM5a toward the vector-
borne flaviviruses. Surprisingly, both rhTRIM5a and hTRIM5a
possessed potent antiviral function against specific flaviviruses
within the TBEV serogroup but not toward mosquito-borne flavi-
viruses. The antiviral activity of TRIM5a was mediated through
interactions with the viral protease NS2B/3 at sites of virus repli-
cation, and association of TRIM5a with NS2B/3 from a sensitive
virus resulted in proteasomal degradation of the viral protein.
Importantly, hTRIM5a contributed significantly to the antiviral ef-
fects of type I IFN against sensitive tick-borne viruses. However,
TRIM5a was ineffective against important mosquito-borne flavi-
viruses, including YFV, DENV, and ZIKV. Thus, this work reveals
an unexpected role for primate TRIM5a as an anti-flavivirus
restriction factor that may influence human susceptibility to
infection.
RESULTS
TRIM5a Is a Functional Restriction Factor for
Flaviviruses
The association of various mosquito-borne flaviviruses with
primates prompted us to test whether ectopic expression of
TRIM5a might have anti-flavivirus activity. HEK293 cells were
engineered to stably express various TRIM5a proteins (Fig-
ure S1A). The expression of rhTRIM5a restricted infection of
vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped
HIV-1 in 293 cells, demonstrating that these cells are appropriate
to observe TRIM5-mediated restriction (Figure S1B). Compared
to empty vector control cells, expression of either hTRIM5a or
rhTRIM5a restricted replication of related viruses in the TBEV
serogroup, including TBEV (strain Sofjin), Kyasanur Forest
disease virus (KFDV), and Langat virus (LGTV; an attenuated
member of the TBEV serocomplex) but not WNV (strain NY99),
DENV (strain NGC, serotype 2), ZIKV (strain 2013 French Polyne-
sia), or YFV (strain 17D) (Figure 1A). TRIM5a did not affect
replication of Powassan virus (POWV; strain LB) despite this vi-
rus also belonging to the TBEV serogroup. The impact of
hTRIM5a or rhTRIM5a on replication of sensitive flaviviruses
was significant, reducing the production of infectious virus by
up to 1,000-fold during the exponential phase of virus growth.
hTRIM5a was functional but less efficient, imposing a 90%
reduction, but this may be attributable to the lower expression
of hTRIM5a compared to rhTRIM5a (Figure S1A). Therefore,
we also used CrFK cells stably expressing hTRIM5a-hemagglu-
tinin (HA) as a cell model historically used to examine retrovirus
restriction as they lack intrinsic TRIM5a expression (Zhang
et al., 2006). Expression of hTRIM5a suppressed replication of
both TBEV (Figure S1C) and LGTV (an attenuated member of
the TBEV serocomplex) (data not shown) but not WNV (Fig-
ure S1D). In HEK293 cells that support more optimal flavivirus
growth, restriction was observable up to a starting multiplicity
of infection (MOI) of 10 (Figure S1E), but replication of TRIM5a-
sensitive viruses eventually overcame restriction, which is
consistent with viral saturation of antiviral restriction factors
(Cowan et al., 2002; Figure 1A). A related hTRIM with anti-retro-
virus function, TRIM22 (Tissot and Mechti, 1995), did not impact
replication of TBEV, KFDV, or LGTV, demonstrating a specific
role for TRIM5a in flavivirus restriction (Figure 1A). Suppressed
replication of KFDV was also observed at the level of protein
expression, with reduced accumulation of NS3 in cells express-
ing hTRIM5a-HA or rhTRIM5a-HA compared to the empty vector
controls (Figure 1B). Expression of the E protein of sensitive
(B and C) NS3 protein levels in stable HEK293 cells infected with (B) KFDV or (C) POWV. The western blots are generally representative of 2 or 3 experiments,
unless otherwise stated.
(D) Dot plots depicting an overlay of E protein in empty vector (black) or rhTRIM5a-HA cells (red) infected with LGTV or POWV measured by flow cytometry. The
percentage of cells infected as measured by E protein staining is quantified in the bar graphs (mean ± SD, data from 3 independent experiments in triplicate, *p <
0.05, one-way ANOVA with Sidak post-test).
See also Figure S1.
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viruses was also reduced when examined by flow cytometry
(Figure 1D). However, no reduction in either NS3 by western
blot or E expression by flow cytometry was observed following
POWV infection, supporting flavivirus-species-specific restric-
tion by TRIM5a (Figures 1C and 1D).
To determine if hTRIM5a is a functional restriction factor,
TRIM5 mRNA was depleted by RNAi in A549 cells using lenti-
virus-delivered short hairpin RNA (shRNA), or TRIM5 was
knocked out using CRISPR/Cas9 in Hap1 cells. Cells were left
untreated or treated with IFNb for 6 h prior to infection to upre-
gulate TRIM5 expression and induce an antiviral state. Reduced
TRIM5 expression did not affect the responsiveness of cells to
IFNb as measured by upregulation of canonical ISGs, RSAD2
(viperin), and CXCL10 (Figure 2A). However, depletion of
TRIM5 partially relieved the antiviral effect of IFNb on LGTV (Fig-
ure 2A). Transfection of A549 cells with an independent small
interfering (siRNA) sequence targeted toward hTRIM5a also
increased replication of LGTV but not YFV (Figure 2B). Further-
more, deletion of TRIM5 using CRISPR/Cas9 in Hap1 cells
(Figures S1F and S1G) rescued 2 log10 LGTV replication in
the presence of IFNb (Figure 2C). Virus replication was also
increased for TBEV but not POWV, WNV, ZIKV, DENV, or YFV
(Figure 2C). Together, these results identify TRIM5a as a restric-
tion factor for specific species of flaviviruses and demonstrate
that TRIM5a is an effector of the human type I IFN response
to these viruses.
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Figure 2. Endogenous hTRIM5a Is an ISG Required for the Antiviral Effects of IFNb against TBEV and LGTV
(A) The left panel shows qRT-PCR for TRIM5, RSAD2, orCXCL10mRNA isolated from A549 cells following transduction with lentiviruses expressing short hairpin
RNAs (shRNAs) for GFP (control) or TRIM5, and untreated or treated with IFNb (IFN) at 1000 U/ml for 6 h. The right panel shows LGTV titers in A549 cells that were
left untreated or pre-treated with IFNb for 6 h and infected at anMOI of 0.001. Supernatants were collected at the indicated times and titrated by plaque assay. All
data are from 3 independent experiments performed in triplicate (mean ± SD, *p < 0.05, **p < 0.01 by Mann-Whitney; ns, not significant).
(B) A549 cells were transfected with siRNAs specific for TRIM5 or a non-targeting (NT) control. Cells were infected with LGTV or YFV at 48 h post-transfection
(MOI, 0.001), and supernatants harvested for virus titration 48 h later. Data are from 3 independent experiments (mean ± SD, ***p < 0.001 by unpaired t test one-
tailed). Inset shows the relative TRIM5 mRNA expression measured by qRT-PCR in A549 cells.
(C) Replication of LGTV, TBEV, POWV, WNV, ZIKV, DENV-2, and YFV (all infected at MOI 0.1) in Hap1 cells with TRIM5 gene disruption by CRISPR/Cas9. Hap1
cells were left untreated or pretreated for 6 h with IFNb. Data are from 2–3 independent experiments performed in triplicate (mean ± SD, ***p < 0.001, ****p <
0.0001 by one-way ANOVA with Tukey’s multiple comparisons post-test; ns, not significant).
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TRIM5a Expression Restricts Viral RNA Replication
To determine which step in the flavivirus life cycle was restricted
by TRIM5a, LGTV replication was examined in rhTRIM5a-HA
HEK293 cells. At 48 h post-infection (hpi), supernatants and
cell lysates were subjected to three cycles of freeze-thaw lysis
to compare levels of intra- and extracellular virus. In the pres-
ence of rhTRIM5a, no change in the ratio (1:10) of intracellular:
extracellular infectious virus was observed (Figure 3A), although
intracellular accumulation of positive-sense (genomic) viral RNA
was reduced by approximately 50-fold (Figure 3B). Viral entry
was not affected, as differences in positive-sense RNA were
not apparent after virus entry until at least 8–12 hpi when flavivi-
rus RNA replication is initiated (Chu and Westaway, 1985; Lin-
denbach et al., 2007; Figure 3C). Thus, TRIM5a imposes a block
in virus replication at or preceding RNA replication without
affecting virus entry or release. In flavivirus-infected cells, cellular
localization of double-stranded RNA (dsRNA) is an obligate
marker of sites of replication, and most perinuclear foci contain-
ing NS3 (the viral protease and RNA helicase) also colocalize
with dsRNA, suggesting these perinuclear foci are sites of active
replication (Westaway et al., 1997; Figure S2A). In infected cells,
small aggregates of rhTRIM5a often termed cytoplasmic bodies
(Diaz-Griffero et al., 2006) colocalized with NS3 and dsRNA,
suggesting that TRIM5a is recruited to replication complexes
dsRNA
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Figure 3. TRIM5a Restricts Flavivirus RNA Replication and Co-precipitates with the Viral Protease NS2B/3
(A) HEK293 cells with stable expression of rhTRIM5a-HA or the empty vector (control) were infected with LGTV (MOI of 0.01). Infectious virus in cell supernatants
or intracellular virus was quantified by plaque assay at 48 hpi (mean ±SD, data from 3 independent experiments in triplicate, *p < 0.05 one-tailed, Mann-Whitney).
(B) Accumulation of LGTV positive-sense viral RNA in cells infected in (A) was determined at 48 hpi by qRT-PCR (mean ±SD, *p < 0.05; ***p < 0.001, unpaired t test
from 3 independent experiments in triplicate).
(C) Changes in genomic RNA over time following binding of LGTV to control and rhTRIM5a-HA-expressing HEK293 cells at 4C and three washes with DPBS
(mean ± SD, ****p < 0.0001, 2-way ANOVA with Sidak’s post-test from 3 independent experiments in triplicate).
(D) Colocalization of NS3 (red), dsRNA (greyscale), and rhTRIM5a (green) in HEK293 rhTRIM5a-HA LGTV-infected cells at 24 hpi by IFA (MOI of 5). Scale
bar, 10 mm.
(E) Colocalization of NS3 (red) or NS5 (red) and rhTRIM5a (green) in HEK293 rhTRIM5a-HA LGTV-infected cells at 24 hpi by IFA. Nuclei are counterstained with
40,6-diamidino-2-phenylindole (DAPI; blue) (MOI of 5). Scale bar, 10 mm.
(F) Interactions between rhTRIM5a or hTRIM5awith NS3 at 48 hpi with LGTV shown by immunoprecipitation (IP) of NS3 from infected HEK293 cells. WCE, whole-
cell extract.
See also Figure S2.
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(Figures 3D). RhTRIM5a aggregates also colocalized with NS5
(the viral RdRP) but only at perinuclear sites likely together with
NS3 at the endoplasmic reticulum (ER) (Figure 3E). Recruitment
of hTRIM5a to sites of NS3 expression was also observed in
LGTV-infected cells (Figure S2B). Areas of colocalization were
observable between TRIM5a and dsRNA in the context of
DENV or ZIKV, but infection did not induce strong aggregation
of TRIM5a (Figures 4A and 4B). Next, we validated the associa-
tion of either hTRIM5a or rhTRIM5a with NS3 by immunoprecip-
itation (IP) in LGTV-infected cells (Figure 3F). Despite low levels
of viral protein associated with restriction, IP of NS3 from in-
fected cells resulted in co-precipitation with either hTRIM5a or
rhTRIM5a (Figure 3F). As expected, NS5 also co-precipitated
with NS3 in infected cells, which supports the immunofluores-
cence assay (IFA) data and suggests that TRIM5a interactions
with NS3 occur at sites of virus replication where NS3 and NS5
interact. Consistent with a lack of TRIM5a aggregation at sites
of dsRNA staining (Figures S2C and S2D), IP of NS3 from
WNV-infected cells did not result in co-precipitation of rhTRIM5a
(Figure S2E). Thus, TRIM5a localizes to viral replication com-
plexes and suppresses RNA replication in a flavivirus-specific
manner.
TRIM5a Targets the Flavivirus Protease for Proteasomal
Degradation
To examine interactions with NS3 and NS5 separately, stable
rhTRIMa-HA cells were transfected with plasmids encoding
LGTV NS2B/3 or NS5. NS2B was included as it forms an integral
structural component of the NS3 protease active site and trans-
membrane domains within NS2B target NS3 to ER membranes,
with NS2B/3 being an important antiviral drug target (Luo et al.,
2015). NS5 showed some co-localization with rhTRIM5a (Fig-
ure 5A) and caused low levels of TRIM5a aggregation (Figure 5B)
but did not co-precipitate (Figure S3A). However, NS2B/3
expression caused rhTRIM5a to aggregate into discrete cyto-
plasmic bodies (Figures 5A, 5B, and S3B) and co-localize remi-
niscent of that observed following virus infection, and LGTV
NS2B/3 strongly associated with rhTRIM5a by co-precipitation
(Figure 5G). In addition, expression levels of NS2B/3 were
reduced in cells expressing rhTRIM5a compared to the control
cell line, whereas NS5 levels were not strongly affected (Fig-
ure 5C). To further explore this observation, a constant level of
LGTV NS2B/3 was expressed with increasing amounts of either
rhTRIM5a or hTRIM5a by transfection of expression plasmids. In
either case, expression of both unprocessed NS2B/3 and NS3
generated through autonomous cleavage was reduced in a
dose-dependent fashion (Figures 5D and 5E), although this ef-
fect was quickly saturated. Again, the expression of LGTV NS5
was not affected by rhTRIM5a expression (Figure 5F).
In the context of HIV-1, TRIM5a utilizes the proteasome
(MG132 sensitive) for capsid disruption but not for restriction
(Kutluay et al., 2013) andmay also use lysosomes following auto-
phagy (BafA1-sensitive) to degrade the capsid (Mandell et al.,
2014a; Ribeiro et al., 2016). Treatment of NS2B/3-expressing
cells with BafA1 to inhibit lysosomal degradation increased the
expression of NS2B/3 when expressed alone but did not rescue
the relative loss of NS2B/3 in the presence of rhTRIM5 (Figures
5H and 5I). This was despite the BafA1-sensitive rescue of
p62/SQSTM1, which is a reported co-factor to TRIM5-mediated
retrovirus restriction (O’Connor et al., 2010; Figure 5H). Selective
autophagy of the HIV-1 capsid by TRIM5a is also mediated by
Beclin, ATG5, p62, GABARAP, and LC3 (Mandell et al., 2014a),
but siRNA-mediated knock down of these genes did not signifi-
cantly relieve LGTV restriction (Figures S4A–S4C). Finally, the
C-type lectin langerin, but not DC-SIGN, was previously shown
to be sufficient for autophagic degradation of the HIV-1 capsid
by hTRIM5a (Ribeiro et al., 2016). However, although DC-SIGN
augmented LGTV replication as expected in its role as a flavivirus
attachment factor (Davis et al., 2006), langerin expression had
no effect and did not further increase the restriction of LGTV in
TRIM5a-expressing cells (Figure S4D), strongly suggesting that
selective autophagy following virus entry or establishment of
viral replication complexes is not the main mechanism of restric-
tion. In contrast, treatment with epoxomicin (Figures 5H and 5I)
recovered the majority of NS3 in the presence of rhTRIM5a,
implicating proteasomal degradation of NS2B/3. This was sup-
ported by reciprocal IP of NS2B/3 ectopically co-expressed
with rhTRIM5 in the presence of epoxomicin demonstrating (1)
increased interactions between TRIM5a and both the uncleaved
NS2B/3 precursor and themature, autocleavedNS3 protein, and
(2) increased ubiquitination of NS2B/3 co-precipitating with
TRIM5a (Figure 5G). TRIM5a did not appear to affect protease
activity, as autocleavage to produce NS3 measured by the ratio
of NS2B/3:NS3 did not change in the presence of TRIM5a (Fig-
ure S4E). Furthermore, overexpression of K48R-HA ubiquitin
(Ub) that cannot make K48-linked Ub chains, but not K63R-HA
Ub, rescuedexpressionofbothNS2B/3and rhTRIM5a (Figure5J),
further suggesting that NS2B/3 degradation involves K48-linked
ubiquitination, which generally involves the proteasome.
To determine the domain of NS2B/3 recognized by TRIM5a,
degradation assays were performed on various truncated NS2B/
3 constructs (Figure 5K). NS3 expressed without NS2B (Fig-
ure S4F) or the NS3 helicase domain alone (Figure S4G) was
not sufficient for TRIM5a-mediated degradation. A construct
containing the entire NS2B protein fused to the NS3 protease
domain (NS2B-NS3pro) was also not degraded, suggesting
that NS2B alone is not sufficient as a target (Figure S4H).
However, expression of NS3pro containing the 40 amino acids
of NS2B required for NS3 protease activity in frame with a flex-
ible glycine linker, the NS3 protease domain and the linker
sequence between the NS3 protease and helicase domains,
enabled degradation (Figure 5L). Thus, the target for TRIM5a
degradation requires NS2B in addition to NS3 sequences
(NS3pro). Recognition of NS2B/3 is, therefore, likely dependent
on protease conformation but is independent of protease
activity, as the S138A active site mutant of NS2B/3 was also
degraded (Figure S4I).
TRIM5a Interaction with the Flavivirus Protease Is
Associated with Virus Restriction
The N terminus of TRIM proteins is composed of a RBCC motif,
which includes a really interesting new gene (RING) domain, one
or more B-box domains, and a coiled-coiled (CC) domain (Lu-
ban, 2012). The RING and B-box can mediate conjugation of
Ub, thereby functioning as an E3 Ub ligase, whereas the CC
domain allows oligomerization of TRIM proteins and formation
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Figure 4. rhTRIM5a Does Not Form Cytoplasmic Bodies at Sites of dsRNA during Replication of ZIKV or DENV
(A) Stable rhTRIM5a-HA cells were infected with LGTV (MOI 5), ZIKV (MOI 0.01), or DENV (MOI 0.01) and stained for dsRNA (red) and rhTRIM5a (green) at 24 hpi.
Nuclei were counterstained with DAPI. Scale bar, 10 mm. Insets show the region indicated by a white box.
(B) Examples of the intensity profiles along vectors drawn through dsRNA staining in 3 fields of rhTRIM5a-HA cells infectedwith LGTV, ZIKV, or DENV (mean ±SD,
****p < 0.0001, 2-way ANOVA with Sidak’s post-test). Asterisks indicate colocalization between rhTRIM5a-HA and concentrations of dsRNA as measured by
intensity along vectors.
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of cytoplasmic bodies (Fletcher et al., 2018). The specificity of
TRIM proteins is mainly determined by their C-terminal B30.2/
SPRY domain that is responsible for binding to specific sub-
strates, including retroviral capsids (Sawyer et al., 2005). The
C15/18A RING mutant of rhTRIM5a did not degrade NS2B/3
(Figure 6A) and instead stabilized it consistent with retention
of binding (Figure 6B). Restriction of infectious virus produc-
tion was also dependent on rhTRIM5a RING function, particu-
larly at early times post-infection (Figure 6D). Compared to
co-expression of LGTV NS2B/3 with WT-rhTRIM5a-HA, the
C15/18A RING mutant retained strong colocalization by IFA
but lost the ability to form discrete cytoplasmic bodies (Fig-
ures 6E and 6F). In contrast, deletion of the B30.2/SPRY
domain eliminated degradation of NS2B/3 (Figure 6A) associ-
ated with failure to bind NS3 in infected cells (Figure 6C),
reduced colocalization with ectopically expressed NS2B/3
(Figure 6F), and the loss of antiviral activity (Figure 6D). Impor-
tantly, these data directly link TRIM5a binding and degrada-
tion of NS2B/3 to its antiviral restriction capacity in the context
of flaviviruses.
In the context of retroviruses, capsid binding by cyclophilin A
(CypA) is required for virus replication (Gamble et al., 1996;
Luban et al., 1993), and substitution of the B30.2/SPRY domain
of hTRIM5a with CypA facilitates hTRIM5a binding to HIV-1 and
virus restriction (Luban, 2007, 2012). The tick-borne flaviviruses,
including LGTV, are sensitive to Cyp inhibition (Figure S5A;
Chiramel et al., 2016), and CypA specifically is required for
efficient virus replication (Figure S5B). However, although sub-
stitution of owl monkey CypA (Sayah et al., 2004) or human
CypA (Gamble et al., 1996) for the hTRIM5a B30.2/SPRY
domain suppressed replication of VSV-G pseudotyped HIV-1
(Figures S1A and S1B), these fusion proteins had no effect on
replication of LGTV (Figures S5C and S5D). Thus, although
CypA is required for flavivirus replication and binds to NS pro-
teins NS5 (Qing et al., 2009) and NS4B (Vidotto et al., 2017)
within viral replication complexes, TRIM5-CypA fusion proteins
are not sufficient to restrict tick-borne flavivirus replication, con-
firming the importance of the B30.2/SPRY domain of TRIM5a in
flavivirus restriction.
Endogenous hTRIM5a Is an Antiviral Restriction Factor
for Flaviviruses
The role of hTRIM5a in suppression of HIV-1 has been controver-
sial, in part because early studies suggested no restriction of lab-
oratory strains of HIV-1. However, recent studies suggest that
cytotoxic T lymphocyte (CTL)-selected HIV-1 isolates from
so-called ‘‘elite controllers’’ are susceptible to restriction by
hTRIM5a (Merindol et al., 2018), and genetic studies suggest
that human polymorphisms in TRIM5 impact disease progres-
sion (Merindol and Berthoux, 2015). To further examine whether
TRIM5a in human cells restricts flavivirus replication, we first
immunoprecipitated LGTV NS2B/3 following ectopic expression
in unmodified HEK293 cells, which revealed an interaction with
endogenous TRIM5a (Figure 7A). Treatment of these cells with
epoxomicin increased the levels of co-precipitating TRIM5 and
NS2B/3 as well as the presence of endogenous K48-linked Ub
smears in the complex (Figure 7B), whereas depletion of TRIM5a
byCRISPR/Cas9-mediated gene editing both increased levels of
NS3 and decreased endogenous K48-linked Ub smears in the
precipitates (Figure 7C). Endogenous interactions between
NS3 and TRIM5awere also confirmed in the HAP1 cells knocked
out for TRIM5a by CRISPR/Cas9 and infected with LGTV (Fig-
ure 7D). Finally, infection of primary human-monocyte-derived
dendritic cells (DCs) resulted in upregulation of TRIM5 expres-
sion (Figure 7E). Silencing of TRIM5 expression in human DCs
by lentivirus-delivered shRNA expression (Pertel et al., 2011)
increased the release of infectious KFDV by approximately
170-fold at 48 hpi compared to cells expressing shRNA specific
for luciferase as a control (Figures 7F and 7G). No effect of
TRIM5a silencing was observed following infection with ZIKV
(Figure 7H). Together, these data demonstrate that hTRIM5a is
a bona fide restriction factor for specific flaviviruses that func-
tions through interactions with the viral replication complex
and proteasomal degradation of NS3.
Figure 5. Binding of the Flavivirus Protease by rhTRIM5a Is Conformation-Dependent and Results in Proteasome-Dependent Degradation of
NS2B/3
(A) Stable HEK293 rhTRIM5a-HA (green) cells were transfected with plasmids coding for either NS2B/3-V5 or NS5-V5 (red) from LGTV and imaged by confocal
microscopy. Scale bar, 10 mm.
(B) Relative intensity of TRIM5 aggregates were measured along vectors drawn in 3 fields of cells expressing LGTV NS2B/3 or NS5, with example vectors shown
in Figure S3B (mean ± SD, ****p < 0.0001, 2-way ANOVA with Dunnett’s post-test).
(C) Western blot of LGTV NS2B/3-V5 or NS5-V5 in stable rhTRIM5a-HA or control HEK293 cells.
(D–F) Western blot analysis of HEK293 cells transfected with (D) increasing amounts of rhTRIM5a-HA and constant amounts of LGTV NS2B/3-V5, (E)
increasing amounts of hTRIM5a-HA and constant amounts of LGTV NS2B/3-V5, and (F) increasing amounts of rhTRIM5a-HA and constant amounts of LGTV
NS5-V5.
(G) Reciprocal coIP of rhTRIM5a-HA and LGTV NS2B/3-V5 following cotransfection and 4 h treatment with epoxomicin (200 nM). The asterisk indicates a non-
specific band.
(H) Western blot of LGTV NS2B/3-V5, rhTRIM5a-HA, and endogenous p62 in HEK293 cells following 4 h treatment with DMSO (vehicle), Baf-A1 (200 nM), or
epoxomicin (200 nM).
(I) Quantification of LGTV NS2B/3 expression with or without rhTRIM5a and treated with Baf-A1 or epoxomicin from 11 individual experiments (mean ± SD, **p <
0.01, 2-way ANOVA with Sidak’s post-test).
(J) LGTV NS2B/3-V5 and rhTRIM5a-FLAG were co-expressed with ubiquitin (Ub)-HA wild type (WT) or K48R or K63R mutants in HEK293 cells. Target proteins
were immunoprecipitated using anti-V5 or anti-FLAG antibodies and blots probed with anti-HA to examine Ub conjugation.
(K) Domain structure of flavivirus NS2B/3 (PDB: 2vbc) and schematic representation of truncation mutants.
(L) Western blot analysis of HEK293 cells transfected with increasing amounts of rhTRIM5a-HA and constant amounts of LGTV NS3pro. Lysates were probed
specifically for HA, V5 and b-actin.
See also Figure S3 and S4.
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Figure 6. TRIM5a Interaction with the Flavivirus Protease Is Associated with Virus Restriction
(A) Western blot analysis following transfection of constant amounts of LGTV NS2B/3-V5 plasmid with increasing amounts of rhTRIM5a-HA, RING mutant
rhTRIM5(C15/C18A)-HA, or rhTRIM5-delta SPRY-HA, as indicated in HEK293 cells.
(B and C) IP of NS3 from LGTV-infected HEK293 cells (MOI of 0.01; 48 hpi) stably expressing (B) RING rhTRIM5(C15/C18A)-HA or (C) rhTRIM5a-HA or rhTRIM5-
delta SPRY-HA.
(legend continued on next page)
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DISCUSSION
TRIM5a functions as an intrinsic cellular restriction factor that
recognizes retrovirus capsids with high specificity and with
definitive consequences for primate susceptibility to HIV-1 infec-
tion (Ganser-Pornillos et al., 2011; Hatziioannou et al., 2006;
Merindol and Berthoux, 2015; Stremlau, 2007; Stremlau et al.,
2004; Stremlau et al., 2006; Wu et al., 2013). Here, we show
that both hTRIM5a and rhTRIM5a restrict replication of specific
flaviviruses within the TBEV serocomplex and that endogenous
TRIM5a is required for the antiviral effects of type I IFN against
sensitive flaviviruses in human cells. The viruses sensitive to
TRIM5a included TBEV, KFDV, and LGTV but interestingly not
POWV. However, mosquito-borne YFV, DENV, ZIKV, and WNV
were not sensitive to rhTRIM5a-mediated restriction. We further
identified the viral protease NS2B/3 as amajor target recognized
by the SPRY/B30.2 domain of TRIM5a. NS2B/3 is responsible
for a number of cleavage events of the viral polyprotein, and
NS3 additionally encodes the RNA helicase essential to viral
RNA replication (Lindenbach et al., 2007). NS3 also contributes
to virus particle assembly (Gebhard et al., 2016), and NS2B/3
has been shown for some flaviviruses to cleave host proteins
involved in antiviral sensing and production of type I IFN (Aguirre
et al., 2012; Yu et al., 2012). Thus, the essential role of NS2B/3 in
virus replication explains the generalized effect of TRIM5a in
reducing viral RNA replication, protein expression, and produc-
tion of infectious progeny. Taken together, this work significantly
extends the paradigm of TRIM5a as an antiviral restriction factor
and suggests that, in contrast to the current view, TRIM5a ex-
hibits a remarkable plasticity in recognition of unrelated viruses.
The precise molecular determinant recognized by TRIM5a
was not finely mapped but required both the cytoplasmic
domain of NS2B that contributes to NS3 protease structure
and function, as well as the linker region between protease
and helicase domains. The linker domain is functionally impor-
tant in directing the conformation of the viral helicase relative
to the ER membrane and to the protease domain in order to
regulate polyprotein processing and genome replication (Luo
et al., 2010). Thus, binding of the linker domain by TRIM5a
may result in steric hindrance of NS3 function in addition to pro-
tein degradation. Indeed, mutation of the TRIM5a RING domain
prevented NS3 degradation but was still able to impact a weak
level of restriction of LGTV replication. The requirement for
NS2B sequences that contribute to the protease structure sug-
gests that the binding requirements of TRIM5a are dependent
on NS2B/3 conformation. Interestingly, targeting the E3 ligase
activity of TRIM5 to sites of tick-borne flavivirus replication
through fusion with CypA is not sufficient to restrict infection,
despite a clear requirement for CypA in flavivirus replication
(Chiramel et al., 2016; Qing et al., 2009; Vidotto et al., 2017),
perhaps because CypA binds to different NS proteins (NS5,
NS4A) (Qing et al., 2009; Vidotto et al., 2017) than does TRIM5a.
These results suggest highly coordinated activities of the SPRY/
B30.2 and RING domains in NS2B/3 binding and effector func-
tions, respectively. Therefore, thorough mapping and structural
studies are required to precisely delineate TRIM5a interactions
with NS2B/3 and how this compares with known structural de-
terminants governing the TRIM5a interaction with retrovirus
capsid lattices.
The rapid evolution of the TRIM5 gene throughout primate
evolution is associated with selection pressure from lentivirus
capsid sequences (McCarthy et al., 2015). It is, therefore, unclear
how evolutionary selection of TRIM5a for retrovirus restriction
has left the protein with enough flexibility to maintain antiviral
activity against flaviviruses. It may be possible that ancient flavi-
virus-like viruses have influenced the evolution of hTRIM5a.
However, the time frame of flavivirus evolution is in the order of
thousands of years in contrast tomillions of years for retroviruses
and the TRIM5 gene (Kaiser et al., 2007). Flaviviridae includes the
more ancient genera of Hepaciviruses, although evidence for a
zoonotic origin of hepatitis C virus (HCV) in non-human primates
is not strong despite the extremely narrow host range of HCV
limited to humans and chimpanzees (Simmonds, 2013). There-
fore, it seems unlikely that flaviviruses influenced the positive se-
lection of the TRIM5 gene within the human lineage. However,
our work raises the possibility that human polymorphisms within
the TRIM5 locus could influence resistance to infection with
medically important flaviviruses. Thus, understanding the ge-
netic trade-offs in both TRIM5a and NS2B/3 that enable restric-
tion of flaviviruses versus retroviruses represent an important
model to illustrate how host resistance is shaped by multiple
pathogens and might provide new insight to human susceptibil-
ity to emerging flaviviruses.
Among the tick-borne flaviviruses tested, POWV was insensi-
tive to TRIM5a-mediated restriction. This raises the question of
how flaviviruses escape restriction and whether this has implica-
tions for host tropism and evolution of these viruses. Despite the
close genetic relationship between POWV and other tick-borne
viruses sharing 80%–87% amino acid identity across NS3, it
is possible that encodes NS2B/3 sequences that are not bound
by TRIM5a, as was observed for WNV. Alternatively, virus-spe-
cific interactions between the flavivirus replication complex and
CypA might protect against TRIM5 binding, as was recently
reported for HIV-1 (Kim et al, 2019). Finally, it is possible
that some flaviviruses may encode an antagonist of TRIM5a ac-
tivity. Detailed mapping studies to identify viral determinants of
TRIM5a binding and degradationwill shed light on these potential
evasion strategies and will further enable studies examining the
role of TRIM5a in primate immunity to infection.
Although primates have a single TRIM5 gene, rodents have an
expanded clade of TRIM5 genes with at least seven TRIM5 pa-
ralogs in mice that cluster into two groups designated TRIM30
(D) LGTV replication kinetics in HEK293 cells stably expressing rhTRIM5a-HA, RING mutant rhTRIM5(C15/C18A)-HA, rhTRIM5-delta SPRY, or the empty vector
control following infection at MOI of 0.001. All data are from 3 independent experiments in triplicates (mean ± SD, *p < 0.05 Mann-Whitney test).
(E and F) HEK293 cells were co-transfected with LGTV NS2B/3-V5 (shown expressed alone in E), WT rhTRIM5a-HA, RING mutant rhTRIM5(C15/C18A)-HA, or
rhTRIM5-delta SPRY-HA (F). Slides were fixed and processed for indirect immunofluorescence staining with antibodies specific for HA (green) and V5 (red), and
nuclei were counterstained with DAPI (blue). Imageswere analyzed using confocal microscopy with fluorescence intensity profilesmeasured across thewhite line
of insets to demonstrate colocalization using Zen Imaging software. Scale bar, 10 mm. See also Figure S5.
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Figure 7. Endogenous hTRIM5a Is an Antiviral Restriction Factor for Flaviviruses
(A) IP of LGTV NS2B/3-V5 following ectopic expression in unmodified HEK293 cells and probed for TRIM5.
(B) IP of LGTV NS2B/3-V5 following ectopic expression and epoxomicin treatment in unmodified HEK293 cells. Western blots were probed for TRIM5 and K48-
linked ubiquitin.
(C) IP of LGTV NS2B/3-V5 following ectopic expression in HEK293 cells transfected with plasmids encoding TRIM5 gRNA and Cas9. Western blots were probed
for TRIM5 and K48-linked ubiquitin.
(D) HAP1 control and TRIM5/ cells were infected with LGTV (MOI 0.1), andNS3was immunoprecipitated at 48 hpi. Western blots were probed for TRIM5, NS3,
and NS5.
(E and F) TRIM5 mRNA expression in primary human MDDCs (E) infected with LGTV (MOI 5 at 24 hpi) or (F) transduced with lentiviruses expressing shRNA-Luc
(control) or shRNA-TRIM5 (mean ± SD from 3 experiments in triplicates, *p < 0.0001, unpaired t test).
(G) KFDV titers or (H) ZIKV titers following infection of human MDDCs generated in (F). (MOI of 0.1; mean ± SD from 1 of 2 experiments performed, ****p < 0.0001
one-way ANOVA with Sidak post-test).
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and TRIM12 (Tareen et al., 2009). TRIM12 genes possess anti-
retroviral activity, although a function in retrovirus restriction
has not been observed for TRIM30 genes (TRIM30-a, -b, -c,
and -d) (Lascano et al., 2015; Tareen et al., 2009). We previously
demonstrated that TRIM30-d (also known as TRIM30-3 or
TRIM79) restricts replication of a subset of flaviviruses within
the TBEV serogroup (Taylor et al., 2011). TRIM30-d interacted
with and degraded the viral NS5 protein that is essential for virus
replication owing to its MTase and RdRP functions and its role as
an antagonist of IFN-I-dependent signaling (Best, 2017; Best
et al., 2005; Laurent-Rolle et al., 2010). TRIM30-d directed the
destruction of NS5 complexed with NS3 by lysosomes, consis-
tent with the ability of lysosomes to accommodate the degrada-
tion of large protein complexes (potentially through autophagy)
(Mandell et al., 2014b; Sparrer et al., 2017), although TRIM30-
d did not degrade NS2B/3 expressed in the absence of NS5
(Taylor et al., 2011). Like TRIM5a, restriction of virus replication
by TRIM30-d appeared specific to tick-borne flaviviruses,
including LGTV, POWV, and TBEV, because TRIM30-d did not
inhibit the replication of WNV (Taylor et al., 2011). Rodents are
required for the maintenance of tick-borne flaviviruses in nature
by enabling tick co-feeding and transfer of virus from infected to
uninfected ticks in the absence of detectable viremia (Kazimı´rova´
et al., 2017). However, despite the parallels in antiviral activity
between TRIM30-d and TRIM5a, it is unlikely that flavivirus
sensitivity to TRIM30-d directly influenced sensitivity to primate
TRIM5a, as the targeted viral proteins and mechanisms of
antiviral activity are unrelated. Instead, the evolutionary history
of tick-borne flaviviruses in rodents suggests that the TRIM30-
d/NS5 interaction has arisen independently to TRIM5/NS2B-3
interactions.
In summary, the finding that primate TRIM5a can recognize
and degrade NS2B/3 from specific flaviviruses combined with
a strong antiviral role in the type I IFN response suggests that
TRIM5 has a high potential to function as an important human
barrier to infection with emerging flaviviruses. We speculate
that resistance to TRIM5a-mediated restriction may be an
important factor in enabling the use of primates as reservoirs
for viruses such as YFV, DENV, and ZIKV. Regardless, these
findings reveal an alternative model to retroviruses to explore
the structure and function of TRIM5a in human resistance to vi-
rus infection.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d EXPERIMENTAL MODEL AND SUBJECT DETAILS
B Cell Culture
B Generation of human monocyte derived dendritic cells
(DCs)
d METHOD DETAILS
B Inhibitors
B Virus Infections and Lentivirus production
B Expression constructs
B Generation of stable cells lines
B Antibodies
B Immunoprecipitation (IP) and Western Blot Analysis
B Confocal Microscopy
B Flow cytometry
B RNA Isolation and quantitative RT-PCR
B RNA interference
B Quantification and statistical analysis
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.
celrep.2019.05.040.
ACKNOWLEDGMENTS
This work was supported by the Division of Intramural Research of the
National Institute of Allergy and Infectious Diseases (NIAID), NIH, by NIH
grants R01AI111809 and DP1DA034990 to J.L. and RO1AI137011 and
DP1DA046108 to S.L.S. S.L.S. is a Burroughs Wellcome Investigator in the
Pathogenesis of Infectious Disease. N.R.M. was supported by the PDEP
award from the Burroughs Wellcome Fund.
AUTHOR CONTRIBUTIONS
Conceptualization, A.I.C. and S.M.B.; Methodology, A.I.C., N.R.M., F.B.,
S.L.S., and S.M.B.; Investigation, A.I.C., N.R.M., K.L.M., R.M.B., V.R.M.,
O.M.-S., S.J.R., F.B., G.L.S., K.J.L., V.N., B.H.Y., R.T.T., K.K., and S.M.B.;
Data Curation, A.I.C., N.R.M., F.B., S.M.B.; Writing – Original Draft, A.I.C.
and S.M.B.; Writing – Review & Editing, A.I.C., N.R.M., R.T.T., F.B., S.L.S.,
and S.M.B.; Resources, J.L., V.M.H., R.T.T., S.L.S., and S.M.B.; Visualization,
A.I.C., N.R.M., V.R.M., K.L.M., O.M.-S., S.J.R., G.L.S., K.J.L., V.N., S.L.S., and
S.M.B.; Supervision, J.L., R.T.T., S.L.S., and S.M.B.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: February 8, 2018
Revised: April 11, 2019
Accepted: May 10, 2019
Published: June 11, 2019
REFERENCES
Aguirre, S., Maestre, A.M., Pagni, S., Patel, J.R., Savage, T., Gutman, D., Mar-
inger, K., Bernal-Rubio, D., Shabman, R.S., Simon, V., et al. (2012). DENV
inhibits type I IFN production in infected cells by cleaving human STING.
PLoS Pathog. 8, e1002934.
Berger, G., Durand, S., Goujon, C., Nguyen, X.N., Cordeil, S., Darlix, J.L., and
Cimarelli, A. (2011). A simple, versatile and efficient method to genetically
modify human monocyte-derived dendritic cells with HIV-1-derived lentiviral
vectors. Nat. Protoc. 6, 806–816.
Best, S.M. (2017). TheMany Faces of the Flavivirus NS5 Protein in Antagonism
of Type I Interferon Signaling. J. Virol. 91, e01970-16.
Best, S.M., Morris, K.L., Shannon, J.G., Robertson, S.J., Mitzel, D.N., Park,
G.S., Boer, E., Wolfinbarger, J.B., and Bloom, M.E. (2005). Inhibition of inter-
feron-stimulated JAK-STAT signaling by a tick-borne flavivirus and identifica-
tion of NS5 as an interferon antagonist. J. Virol. 79, 12828–12839.
Brady, O.J., Gething, P.W., Bhatt, S., Messina, J.P., Brownstein, J.S., Hoen,
A.G., Moyes, C.L., Farlow, A.W., Scott, T.W., and Hay, S.I. (2012). Refining
the global spatial limits of dengue virus transmission by evidence-based
consensus. PLoS Negl. Trop. Dis. 6, e1760.
Cell Reports 27, 3269–3283, June 11, 2019 3281
Campbell, E.M., Weingart, J., Sette, P., Opp, S., Sastri, J., O’Connor, S.K.,
Talley, S., Diaz-Griffero, F., Hirsch, V., and Bouamr, F. (2015). TRIM5a-medi-
ated ubiquitin chain conjugation is required for inhibition of HIV-1 reverse tran-
scription and capsid destabilization. J. Virol. 90, 1849–1857.
Chiramel, A.I., Banadyga, L., Dougherty, J.D., Falzarano, D., Martellaro, C.,
Brees, D., Taylor, R.T., Ebihara, H., and Best, S.M. (2016). Alisporivir Has
Limited Antiviral Effects Against Ebola Virus Strains Makona and Mayinga.
J. Infect. Dis. 214, S355–S359.
Chu, P.W., and Westaway, E.G. (1985). Replication strategy of Kunjin virus:
evidence for recycling role of replicative form RNA as template in semiconser-
vative and asymmetric replication. Virology 140, 68–79.
Cowan, S., Hatziioannou, T., Cunningham, T., Muesing, M.A., Gottlinger, H.G.,
and Bieniasz, P.D. (2002). Cellular inhibitors with Fv1-like activity restrict
human and simian immunodeficiency virus tropism. Proc. Natl. Acad. Sci.
USA 99, 11914–11919.
Davis, C.W., Nguyen, H.Y., Hanna, S.L., Sa´nchez, M.D., Doms, R.W., and Pier-
son, T.C. (2006). West Nile virus discriminates between DC-SIGN and
DC-SIGNR for cellular attachment and infection. J. Virol. 80, 1290–1301.
Diaz-Griffero, F., Li, X., Javanbakht, H., Song, B., Welikala, S., Stremlau, M.,
and Sodroski, J. (2006). Rapid turnover and polyubiquitylation of the retroviral
restriction factor TRIM5. Virology 349, 300–315.
Fletcher, A.J., Vaysburd, M., Maslen, S., Zeng, J., Skehel, J.M., Towers, G.J.,
and James, L.C. (2018). Trivalent RING Assembly on Retroviral Capsids Acti-
vates TRIM5 Ubiquitination and Innate Immune Signaling. Cell Host Microbe
24, 761–775.e766.
Gamble, T.R., Vajdos, F.F., Yoo, S., Worthylake, D.K., Houseweart, M., Sund-
quist,W.I., andHill, C.P. (1996). Crystal structure of human cyclophilin A bound
to the amino-terminal domain of HIV-1 capsid. Cell 87, 1285–1294.
Ganser-Pornillos, B.K., Chandrasekaran, V., Pornillos, O., Sodroski, J.G.,
Sundquist, W.I., and Yeager, M. (2011). Hexagonal assembly of a restricting
TRIM5alpha protein. Proc. Natl. Acad. Sci. USA 108, 534–539.
Gebhard, L.G., Iglesias, N.G., Byk, L.A., Filomatori, C.V., De Maio, F.A., and
Gamarnik, A.V. (2016). A Proline-Rich N-Terminal Region of the Dengue Virus
NS3 Is Crucial for Infectious Particle Production. J. Virol. 90, 5451–5461.
Han, K., Lou, D.I., and Sawyer, S.L. (2011). Identification of a genomic reservoir
for new TRIM genes in primate genomes. PLoS Genet. 7, e1002388.
Hatziioannou, T., Princiotta, M., Piatak, M., Jr., Yuan, F., Zhang, F., Lifson,
J.D., and Bieniasz, P.D. (2006). Generation of simian-tropic HIV-1 by restriction
factor evasion. Science 314, 95.
Ireland, R., Schwarz, B., Nardone, G., Wehrly, T.D., Broeckling, C.D., Chira-
mel, A.I., Best, S.M., and Bosio, C.M. (2018). Unique Francisella Phosphatidyl-
ethanolamine Acts as a Potent Anti-Inflammatory Lipid. J. Innate Immun. 10,
291–305.
Kaiser, S.M., Malik, H.S., and Emerman, M. (2007). Restriction of an extinct
retrovirus by the human TRIM5alpha antiviral protein. Science 316, 1756–
1758.
Kaul, A., Stauffer, S., Berger, C., Pertel, T., Schmitt, J., Kallis, S., Zayas, M.,
Lohmann, V., Luban, J., and Bartenschlager, R. (2009). Essential role of cyclo-
philin A for hepatitis C virus replication and virus production and possible link
to polyprotein cleavage kinetics. PLoS Pathog. 5, e1000546.
Kazimı´rova´, M., Thangamani, S., Bartı´kova´, P., Hermance, M., Holı´kova´, V.,
Stibra´niova´, I., and Nuttall, P.A. (2017). Tick-Borne Viruses and Biological
Processes at the Tick-Host-Virus Interface. Front. Cell. Infect. Microbiol.
7, 339.
Kim, K., Dauphin, A., Komurlu, S., Yurkovetskiy, L., Diehl, W.E., McCauley,
S.M., Carbone, C., Selyutina, A., Bulnes-Ramos, A., Diaz-Griffero, F., et al.
(2019). Cyclophilin A protects HIV-1 from restriction by human TRIM5a. bio-
Rxiv. https://doi.org/10.1101/587907.
Kutluay, S.B., Perez-Caballero, D., and Bieniasz, P.D. (2013). Fates of retro-
viral core components during unrestricted and TRIM5-restricted infection.
PLoS Pathog. 9, e1003214.
Lascano, J., Uchil, P.D., Mothes, W., and Luban, J. (2015). TRIM5 Retroviral
Restriction Activity Correlates with the Ability To Induce Innate Immune
Signaling. J. Virol. 90, 308–316.
Laurent-Rolle, M., Boer, E.F., Lubick, K.J., Wolfinbarger, J.B., Carmody, A.B.,
Rockx, B., Liu, W., Ashour, J., Shupert, W.L., Holbrook, M.R., et al. (2010). The
NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of
type I interferon-mediated JAK-STAT signaling. J. Virol. 84, 3503–3515.
Lindenbach, B.D., Thiel, H.J., and Rice, C.M. (2007). Flaviviridae: the viruses
and their replication. In Fields Virology, D.M. Knipe and P.M. Howley, eds. (Lip-
pincott Williams & Wilkins), pp. 1101–1152.
Luban, J. (2007). Cyclophilin A, TRIM5, and resistance to human immunodefi-
ciency virus type 1 infection. J. Virol. 81, 1054–1061.
Luban, J. (2012). TRIM5 and the Regulation of HIV-1 Infectivity. Mol. Biol. Int.
2012, 426840.
Luban, J., Bossolt, K.L., Franke, E.K., Kalpana, G.V., and Goff, S.P. (1993). Hu-
man immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B.
Cell 73, 1067–1078.
Luo, D., Wei, N., Doan, D.N., Paradkar, P.N., Chong, Y., Davidson, A.D., Ko-
taka, M., Lescar, J., and Vasudevan, S.G. (2010). Flexibility between the
protease and helicase domains of the dengue virus NS3 protein conferred
by the linker region and its functional implications. J. Biol. Chem. 285,
18817–18827.
Luo, D., Vasudevan, S.G., and Lescar, J. (2015). The flavivirus NS2B-NS3
protease-helicase as a target for antiviral drug development. Antiviral Res.
118, 148–158.
Mandell, M.A., Jain, A., Arko-Mensah, J., Chauhan, S., Kimura, T., Dinkins, C.,
Silvestri, G., M€unch, J., Kirchhoff, F., Simonsen, A., et al. (2014a). TRIM pro-
teins regulate autophagy and can target autophagic substrates by direct
recognition. Dev. Cell 30, 394–409.
Mandell, M.A., Kimura, T., Jain, A., Johansen, T., and Deretic, V. (2014b). TRIM
proteins regulate autophagy: TRIM5 is a selective autophagy receptor medi-
ating HIV-1 restriction. Autophagy 10, 2387–2388.
McCarthy, K.R., Kirmaier, A., Autissier, P., and Johnson, W.E. (2015). Evolu-
tionary and Functional Analysis of Old World Primate TRIM5 Reveals the
Ancient Emergence of Primate Lentiviruses and Convergent Evolution Target-
ing a Conserved Capsid Interface. PLoS Pathog. 11, e1005085.
Merindol, N., and Berthoux, L. (2015). Restriction Factors in HIV-1 Disease
Progression. Curr. HIV Res. 13, 448–461.
Merindol, N., El-Far, M., Sylla, M., Masroori, N., Dufour, C., Li, J.X., Cherry, P.,
Plourde, M.B., Tremblay, C., and Berthoux, L. (2018). HIV-1 capsids from B27/
B57+ elite controllers escape Mx2 but are targeted by TRIM5a, leading to the
induction of an antiviral state. PLoS Pathog. 14, e1007398.
O’Connor, C., Pertel, T., Gray, S., Robia, S.L., Bakowska, J.C., Luban, J., and
Campbell, E.M. (2010). p62/sequestosome-1 associates with and sustains the
expression of retroviral restriction factor TRIM5alpha. J. Virol. 84, 5997–6006.
Pertel, T., Hausmann, S., Morger, D., Z€uger, S., Guerra, J., Lascano, J., Rein-
hard, C., Santoni, F.A., Uchil, P.D., Chatel, L., et al. (2011). TRIM5 is an innate
immune sensor for the retrovirus capsid lattice. Nature 472, 361–365.
Qing, M., Yang, F., Zhang, B., Zou, G., Robida, J.M., Yuan, Z., Tang, H., and
Shi, P.Y. (2009). Cyclosporine inhibits flavivirus replication through blocking
the interaction between host cyclophilins and viral NS5 protein. Antimicrob.
Agents Chemother. 53, 3226–3235.
Rajsbaum, R., Garcı´a-Sastre, A., and Versteeg, G.A. (2014). TRIMmunity: the
roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity.
J. Mol. Biol. 426, 1265–1284.
Ribeiro, C.M., Sarrami-Forooshani, R., Setiawan, L.C., Zijlstra-Willems, E.M.,
van Hamme, J.L., Tigchelaar, W., van der Wel, N.N., Kootstra, N.A., Gringhuis,
S.I., andGeijtenbeek, T.B. (2016). Receptor usage dictates HIV-1 restriction by
human TRIM5a in dendritic cell subsets. Nature 540, 448–452.
Sawyer, S.L., Wu, L.I., Emerman, M., and Malik, H.S. (2005). Positive selection
of primate TRIM5alpha identifies a critical species-specific retroviral restriction
domain. Proc. Natl. Acad. Sci. USA 102, 2832–2837.
3282 Cell Reports 27, 3269–3283, June 11, 2019
Sayah, D.M., Sokolskaja, E., Berthoux, L., and Luban, J. (2004). Cyclophilin A
retrotransposition into TRIM5 explains owlmonkey resistance to HIV-1. Nature
430, 569–573.
Simmonds, P. (2013). The origin of hepatitis C virus. Curr. Top. Microbiol. Im-
munol. 369, 1–15.
Sparrer, K.M.J., Gableske, S., Zurenski, M.A., Parker, Z.M., Full, F., Baumgart,
G.J., Kato, J., Pacheco-Rodriguez, G., Liang, C., Pornillos, O., et al. (2017).
TRIM23mediates virus-induced autophagy via activation of TBK1. Nat. Micro-
biol. 2, 1543–1557.
Stabell, A.C., Meyerson, N.R., Gullberg, R.C., Gilchrist, A.R., Webb, K.J., Old,
W.M., Perera, R., and Sawyer, S.L. (2018). Dengue viruses cleave STING in hu-
mans but not in nonhuman primates, their presumed natural reservoir. eLife 7,
e31919.
Stremlau, M. (2007). GE Prize-winning essay. Why Old World monkeys are
resistant to HIV-1. Science 318, 1565–1566.
Stremlau, M., Owens, C.M., Perron, M.J., Kiessling, M., Autissier, P., and
Sodroski, J. (2004). The cytoplasmic body component TRIM5alpha restricts
HIV-1 infection in Old World monkeys. Nature 427, 848–853.
Stremlau, M., Perron, M., Lee, M., Li, Y., Song, B., Javanbakht, H., Diaz-Grif-
fero, F., Anderson, D.J., Sundquist, W.I., and Sodroski, J. (2006). Specific
recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha
restriction factor. Proc. Natl. Acad. Sci. USA 103, 5514–5519.
Tareen, S.U., Sawyer, S.L., Malik, H.S., and Emerman,M. (2009). An expanded
clade of rodent Trim5 genes. Virology 385, 473–483.
Taylor, R.T., Lubick, K.J., Robertson, S.J., Broughton, J.P., Bloom,M.E., Bres-
nahan, W.A., and Best, S.M. (2011). TRIM79a, an interferon-stimulated gene
product, restricts tick-borne encephalitis virus replication by degrading the
viral RNA polymerase. Cell Host Microbe 10, 185–196.
Tissot, C., and Mechti, N. (1995). Molecular cloning of a new interferon-
induced factor that represses human immunodeficiency virus type 1 long
terminal repeat expression. J. Biol. Chem. 270, 14891–14898.
Vasilakis, N., and Weaver, S.C. (2017). Flavivirus transmission focusing on
Zika. Curr. Opin. Virol. 22, 30–35.
Versteeg, G.A., and Garcı´a-Sastre, A. (2010). Viral tricks to grid-lock the type I
interferon system. Curr. Opin. Microbiol. 13, 508–516.
Vidotto, A., Morais, A.T., Ribeiro, M.R., Pacca, C.C., Terzian, A.C., Gil, L.H.,
Mohana-Borges, R., Gallay, P., and Nogueira, M.L. (2017). Systems Biology
Reveals NS4B-Cyclophilin A Interaction: A New Target to Inhibit YFV Replica-
tion. J. Proteome Res. 16, 1542–1555.
Westaway, E.G., Mackenzie, J.M., Kenney, M.T., Jones, M.K., and Khromykh,
A.A. (1997). Ultrastructure of Kunjin virus-infected cells: colocalization of NS1
and NS3 with double-stranded RNA, and of NS2B with NS3, in virus-induced
membrane structures. J. Virol. 71, 6650–6661.
Wu, F., Kirmaier, A., Goeken, R., Ourmanov, I., Hall, L., Morgan, J.S., Matsuda,
K., Buckler-White, A., Tomioka, K., Plishka, R., et al. (2013). TRIM5 alpha
drives SIVsmm evolution in rhesus macaques. PLoS Pathog. 9, e1003577.
Yu, C.Y., Chang, T.H., Liang, J.J., Chiang, R.L., Lee, Y.L., Liao, C.L., and Lin,
Y.L. (2012). Dengue virus targets the adaptor protein MITA to subvert host
innate immunity. PLoS Pathog. 8, e1002780.
Zhang, F., Hatziioannou, T., Perez-Caballero, D., Derse, D., and Bieniasz, P.D.
(2006). Antiretroviral potential of human tripartite motif-5 and related proteins.
Virology 353, 396–409.
Zhang, R., Miner, J.J., Gorman, M.J., Rausch, K., Ramage, H., White, J.P.,
Zuiani, A., Zhang, P., Fernandez, E., Zhang, Q., et al. (2016). A CRISPR screen
defines a signal peptide processing pathway required by flaviviruses. Nature
535, 164–168.
Cell Reports 27, 3269–3283, June 11, 2019 3283
STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-HA-peroxidase (Clone 3F10) Roche Cat#12013819001; RRID: AB_390917
Anti-HA Zymed Cat #71-5500; RRID: AB_87935
Anti-b-actin Sigma Cat #A5441; RRID: AB_476744
Goat anti-mouse Dako Cat #P0447; RRID: AB_2617137
Anti-rabbit Thermo Scientific Cat #P0448; RRID: AB_2617138
Anti-chicken horseradish peroxidase-conjugated Millipore Cat #12-341; RRID: AB_390189
Anti-mouse V5 Invitrogen Cat #R960-25; RRID: AB_2556564
Anti-chicken LGTV NS3 Customized (Dr. Sonja Best) Previously described in
Taylor et al., 2011
Anti-chicken LGTV NS3 Customized (Dr. Sonja Best) Previously described in
Taylor et al., 2011
Anti-NS3-WNV R&D Systems Cat #AF2907; RRID: AB_562749
Anti-dsRNA antibody J2 English& Scientific Consulting Cat #10010200; RRID: AB_2651015
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Anti-DC-SIGN BD Biosciences Cat #551186; RRID: AB_394087
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Secondary Antibody Alexa 568 (Mouse) Molecular Probes Cat #A11031; RRID: AB_144696
Secondary Antibody Alexa-647 (Chicken) Molecular Probes Cat #A21449; RRID: AB_1500594
Virus Strains
Langat virus (LGTV) Dr. A. Pletnev, NIAID, NIH strain TP21
TBEV (also referred to as Russian spring summer
encephalitis [RSSE] virus)
Dr. M. Holbrook, NIAID, NIH strain Sofjin
Kyasanur forest disease virus (KFDV) Dr. M. Holbrook, NIAID, NIH Strain P96056
Powassan virus (POWV) WRCEVA, UTMB strain LB
West Nile virus WRCEVA, UTMB strain NY99
Dengue virus Dr. Adolfo Garcı´a-Sastre DENV-2, strain New Guinea C
Zika virus (ZIKV) Dr. David Safronetz strains 2013 French Polynesia
and PRABC59
Yellow fever virus (YFV) NIH Biodefense and Emerging Infections
Research Resources Repository, NIAID,
NIH, NR115
strain 17D
HIV-1 virus pseudotyped with VSV-G Dr. Nicholas Meyerson and Dr. Sara Sawyer Universoty of Colorado, Boulder,
pseudotyped with VSV-G and
encoding a GFP reporter
Chemicals, Peptides, and Recombinant Proteins
2 mM L-glutamine Invitrogen Cat #25030-081
Epoxomicin Sigma Cat #E3652
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MG132 Sigma-Aldrich (Calbiochem) Cat #CAS 133407-82-6
Bafilomycin A1 From Streptomyces Griseus Sigma-Aldrich Cat #B1793
Penicillin GIBCO Cat #15140
Puromycin Sigma Cat #B9620
Blasticidin Sigma #CAS 2079-00-7
Polybrene Sigma Cat #107689
Protease inhibitor Roche Cat #11836170001
Protein G-conjugated agarose beads Roche Cat #11719416001
Preciphen Aves, Lab Inc. Cat # P-1010
RIPA buffer Sigma Cat #R0278-500
ProLong Gold Antifade Mountant with DAPI ThermoFisher Scientific Cat #P36931
(Granulocyte-Macrophage Colony Stimulating
Factor) GM-CSF
R&D Systems Cat #215-GM
(Interleukin-4) IL-4 R&D Systems Cat #204-IL
RNase-free DNase ThermoFisher Scientific Cat #EN0521
Critical Commercial Assays
Live/Dead Fixable Aqua Dead Cell Stain Kit ThermoFisher Scientific Cat #L34957
Interferon b (IFNb) PBL Assay Science Cat #11410-2
ECL Plus detection reagent GE Healthcare Cat #RPN2132
Lipofectamine RNAiMAX Transfection Reagent Thermo Fisher Scientific Cat #13778075
Prep RNA/DNA Mini Kit QIAGEN Cat #80204
Superscript III First-Strand Synthesis System Invitrogen Cat #18080-051
ProFection Mammalian Transfection System Promega Cat #E1200
PCR Supermix High Fidelity Thermo Fisher Cat #10790020
Clonase II reaction Invitrogen Cat #11791-100
PfuTurbo DNA polymerase Stratagene Cat #600250
RNeasy kit QIAGEN Cat #74104
PlasmoTest-Mycoplasma Detection Invivo Gen Cat #rep-pt1
Experimental Models: Cell Lines
HEK293T ATCC CRL-3216
HEK293 ATCC CRL-1573
CRFK cells (feline kidney) ATCC CCL-94
A549 ATCC CCL-185
Vero ATCC CCL-81
Oligonucleotides
Probes for qRT-PCR used in this study Applied Biosystems Table S1
siRNAs used in this study (SMARTpool) Horizon (Dharmacon) Table S2
Primers for cloning TRIM5 constructs Integrated DNA Technologies Table S3
shRNA sequence of lentiviral constructs
(Control – Luciferase)
This paper TACAAACGCTCTCATCGACAAG
shRNA sequence of lentiviral constructs
(human TRIM5)
This paper TGCCAAGCATGCCTCACTGCAA
Recombinant DNA
pLPCX Empty Vector Clontech Cat #519 631511
pLPCX human TRIM5 National Institutes of Health AIDS Research
and Reference Reagent Program.
N/A
pLPCX rhesus TRIM5 National Institutes of Health AIDS Research
and Reference Reagent Program.
N/A
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Best (sbest@niaid.nih.gov).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture
HEK293T cells (human embryonic kidney, ATCC; CRL-3216 - fetus sex unknown), HEK293 cells (human embryonic kidney, ATCC;
CRL-1573 - fetus sex unknown), CRFK cells (feline kidney - female, ATCC; CCL-94), A549 cells (lung carcinoma - male, ATCC; CCL-
185) and Vero (sex unknown – ATCC; CCL-81) cells were cultured in Dulbecco’s modified Eagle media (GIBCO; 11995) supple-
mented with 10% fetal bovine serum (GIBCO; 16000-044), 2 mM L-glutamine (Invitrogen; 25030-081), and 1% antibiotics (GIBCO;
15140) (complete media) at 37C and 5% CO2. Near-haploid human cell line derived from male chronic myelogenous leukemia
(CML) - HAP1 cells (Horizon Discovery) was cultured in complete IMDM (GIBCO; 12440053) supplemented with 10% fetal bovine
serum, 2 mM L-glutamine and 1% antibiotics. Human monocyte derived dendritic cells were from both male and female donors.
Generation of human monocyte derived dendritic cells (DCs)
Humanmonocytes enriched by apheresis were obtained fromperipheral blood provided by the Department for TransfusionMedicine
and the National Institutes of Health Clinical Center (NIHCC) at the National Institutes of Health (NIH) [Bethesda, MD] under a protocol
approved by the NIHCC Institutional Review Board. Signed, informed consent was obtained from each donor, acknowledging that
his or her donation would be used for research purposes by intramural investigators throughout the NIH. Monocytes were further
enriched using Ficoll-Paque PREMIUM (GE Healthcare) and were differentiated into hDCs following culture in RPMI 1640 supple-
mented with 10% heat-inactivated FCS, 0.2 mM l-glutamine, 1 mM HEPES buffer, and 0.1 mM nonessential amino acids [complete
RPMI 1640 (cRPMI)] and 100 ng/ml GM-CSF (R&D Systems, #215-GM) and 20 ng/ml IL-4 (R&D Systems, #204-IL) over the course
of 4 d. On day 3 of culture, 100% of each cytokine per well in 1 mL cRPMI was added and cells were used on day 4 of culture. The
resulting differentiated hDCs were > 97% CD1a+/DC-SIGN+ and < 1%CD14+. The hDCs were seeded at 53 105cells per milliliter in
cRPMI.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
pLPCX owl monkey TRIM-CypA Dr. Michael Emerman (Fred Hutchinson
Cancer Research Center
N/A
pcDNA human TRIM22 Dianne Lou CU, Boulder, CO, USA
Langerin expression plasmid Sino Biological HG13040-UT
DC-SIGN expression plasmid Sino Biological HG10200-UT
Constructs expressing LGTV NS2B/3 Previously described in Taylor et al., 2011 N/A
Constructs expressing LGTV NS5 Previously described in Taylor et al., 2011 N/A
Constructs expressing WNV NS2B/3 Previously described in Taylor et al., 2011 N/A
Constructs expressing WNV NS5 Previously described in Taylor et al., 2011 N/A
Lentiviral vectors coding shRNA (Control) Gifted by Prof. Ralf Bartenschlager,
University of Heidelberg, Germany
N/A
Lentiviral vectors coding shRNA (CypA) Gifted by Prof. Ralf Bartenschlager,
University of Heidelberg, Germany
N/A
Lentiviral vectors coding shRNA (CypB) Gifted by Prof. Ralf Bartenschlager,
University of Heidelberg, Germany
N/A
Software and Algorithms
Prism 7 for Mac OS X GraphPad software https://www.graphpad.com
ZEN Imaging Software N/A https://www.zeiss.com/microscopy/
us/products/microscope-software/
zen-lite.html
ImageJ for quantifying western blots ImageJ https://imagej.nih.gov/ij/index.html
Flowjo for flow-cytometry Flowjo Licensed Software
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METHOD DETAILS
Inhibitors
Cell culture grade proteasomal inhibitors epoxomicin (#E3652) and MG132 (#CAS 133407-82-6) were used at 200nM (4 hours) and
10 mg (4 hours) respectively. Lysosomal inhibitor bafilomycin A1 (Baf-A1) (#B1793) was used at 200nM (4 hours).
Virus Infections and Lentivirus production
The viruses used in this study were handled under biosafety level 2 (BSL2), BSL3 and BSL4 conditions at the Rocky Mountain
Laboratories Integrated Research Facility in accordance with DSAT regulations for study of select agents and Institutional
Biosafety approvals (Hamilton, MT). The viruses in this study include: Langat virus (LGTV) strain TP21 (from Dr. A. Pletnev, NIAID,
NIH), TBEV strain Sofjin (also referred to as Russian spring summer encephalitis [RSSE] virus), Kyasanur forest disease virus
(KFDV) [from Dr. M. Holbrook, NIAID, NIH], Powassan virus (POWV, strain LB) and West Nile virus (strain NY99) [from the WRCEVA],
Dengue virus (DENV-2, strain New Guinea C) from Dr. Adolfo Garcı´a-Sastre), Zika virus (ZIKV, strain 2013 French Polynesia, from
Dr. David Safronetz) and Yellow fever virus (YFV, strain 17D), from NIH Biodefense and Emerging Infections Research Resources
Repository, NIAID, NIH, NR115. All viruses were propagated as previously described (Taylor et al., 2011). Cell monolayers were
infected for 1 h at 37C, after which virus inoculum was removed and cells replenished with fresh cell culture medium. Virus titers
are represented as plaque forming units (PFUs) or focus forming units (FFU) per 1 ml.
HIV-1 virus pseudotyped with VSV-G and encoding a GFP reporter for single-cycle infection assays were packaged in 293T
cells seeded at a concentration of 1x106 cells/well in a 6-well dish. One day after seeding, cells were co-transfected with 0.5 mg
pMDLg/pRRE, 0.25mg pRSV-Rev, 0.2mg pMD2.G, and 1mg pRRLSIN.cPPT.PGK-GFP.WPRE (plasmids 60488, 12253, 12252
respectively available from Addgene). Cells were transfected using TransIT-293 at a 1:3 ratio (mg DNA:ml TransIT-293). After 48 hours,
supernatant containing viruses was harvested, filtered, and frozen. For infection assays, CrFK stable cells lines were plated at
a concentration of 7.5x104 cells/well in a 24-well plate or HEK293 stable cell lines were plated at a concentration of 1.0x105 cells/well
in a 24-well plate, and infected with HIV-1 single-cycle virus. Two days post-infection, cells were fixed, washed, resuspended in PBS
supplemented with 1% FBS, and analyzed by flow cytometry for expression of GFP using the BD Bioscience Fortessa cell analyzer.
Lentivirus generation expressing shRNAs
The shTRIM5 and shluciferase lentiviruses were generated by transfecting HEK293T cells with lentivirus shRNA plasmid (pAPM CoE
D4 L1221 or pAPMCoED4 TRIM5 ts2 for shluciferase or shTRIM5, respectively), pSPAX2, and pMD.G using the ProFectionMamma-
lian Transfection System (Promega). pAPM CoE D4 is a truncated derivative of the pAPM lentiviral vector that expresses the puro-
mycin acetyltransferase andmiR30-based shRNA from the SFFV promoter (Pertel et al., 2011). The target sequences are: pAPMCoE
D4 L1221 50-TACAAACGCTCTCATCGACAAG-30 and pAPMCoED4 TRIM5 ts2 50-TGCCAAGCATGCCTCACTGCAA-30. The vpx-vlp
was generated by transfecting 293T cells with pMD.G and SIVMAC packaging plasmid kindly provided by Dr. Andrea Cimarelli (Berger
et al., 2011).Mediawas replaced 18-20 hours post transfection (hpt). Supernatant was harvested at 48 hpt, passed through a 0.45 um
filter, and ultracentrifuged over a cushion consisting of 25% sucrose in TNE buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 100 mM
NaCl, pH 7.4) at 28,000 rpm in a SW-28 Rotor (Beckman). Lentivirus pellets were resuspended in PBS, aliquoted, and stored
at 80C prior to use. shRNA-luc and shRNA-TRIM5 lentivirus titers were normalized by serial dilution on HEK293 cells followed
by puromycin selection.
Knockdown of TRIM5 in Human monocyte-derived dendritic cells (hMDDC) cultures
Human monocyte cultures (Ireland et al., 2018) were seeded in 48-well plates and transduced with a combination of vpx-vlp and
shControl or shTRIM5 lentivirus for three hours followed by addition of IL-4 and GM-CSF-conditioned RPMI media. Conditioned me-
dia was replenished at 3 days post transduction (dpt). Five dpt, cells were collected to confirm knockdown of TRIM5 transcripts by
qRT-PCR. Remaining cells were infected with ZIKV PRABC59 (MOI = 5) or KFDV (MOI = 0.1) for 48 hours. Supernatants were
collected at the indicated times, and virus was measured in the supernatant by limiting dilution plaque assay.
Expression constructs
HA-tagged (C-term) human and rhesus TRIM5 in the pLPCX retroviral vector were obtained from the National Institutes of Health
AIDS Research and Reference Reagent Program. HA-tagged (C-term) owl monkey TRIM-CypA in the pLPCX retroviral vector was
a kind gift from Dr. Michael Emerman (Fred Hutchinson Cancer Research Center). Approximately 5x106 HEK293 cells were used
to isolate RNA with the All Prep RNA/DNA Mini Kit (QIAGEN; 80204). cDNA was generated using 1 mg of RNA with oligo(dT) primers
and the Superscript III First-Strand Synthesis System (Invitrogen; 18080-051). This cDNAwas used as a template to amplify theCypA
coding region (see below). All primers used in this study for to generate constructs or qRT-PCR, along with a description of their use,
can be found in Tables S1 and S3. Human TRIM22 was amplified from a pcDNA3 construct kindly provided by Dianne Lou. TRIM-
CypA constructs were generated by amplifying fragments (aa 1-309 from human TRIM5 in pLPCX and the complete coding sequence
of CypA from HEK293 cDNA) with 20-25bp overlapping regions. Overlapping fragments were spliced together in a PCR reaction
using each fragment as a template and outside flanking primers. Human and rhesus TRIM5delB30.2 constructs were generated
using pLPCX templates and primers that amplify aa 1-276 from human TRIM5 or 1-278 from rhesus TRIM5. All above PCR reactions
were carried out using PCR Supermix High Fidelity (Thermo Fisher; 10790020) with an annealing temperature of 58C. Constructs
were TA-cloned into the gateway entry plasmid pCR8 (Invitrogen; K2500-20). An LR Clonase II reaction (Invitrogen; 11791-100)
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was used tomove these constructs into aGateway-converted pLPCX retroviral packaging vector (Clontech; 631511). The RINGC15/
18A mutant of TRIM5 was generated using PfuTurbo DNA polymerase (Stratagene; 600250) with an annealing temperature of 55C.
Parental pLPCX plasmids were used as a template along with primers containing the mutations of interest. Constructs expressing
LGTV andWNVNY99 NS2B/3 and NS5 were generated as previously described (Taylor et al., 2011). Expression plasmids for Langerin
(HG13040-UT) and DC-SIGN (HG10200-UT) were purchased from Sino Biological.
Generation of stable cells lines
Tomake cell lines that stably express TRIM5 constructs, pLPCX retroviral vectors were used to transduce HEK293 cells. To generate
the retroviruses used for transduction, HEK293T cells were seeded at a concentration of 1x106 cells/well in a 6-well dish. 24 hours
later each well was transfected with 2 mg pLPCX construct (empty or encoding the gene fragment of interest), 1 mg pCS2-mGP en-
coding MLV gag-pol2, and 0.2 mg pC-VSV-G (provided by Hyeryun Choe) at a final 1:3 ratio of DNA to TransIT-293 (mg DNA: ml
TransIT-293). Supernatants were collected after 48 h, passed through a 0.2 mm filter, and used to infect HEK293 cells grown in
complete media. HEK293 cells were seeded in a 12-well dish at a concentration of 7.5x104 cells/well. After 24 h, varying amounts
of retrovirus from each construct were added to cells along with polybrene (Sigma; 107689) at a final concentration of 10 mg/mL. After
24 h, media containing 0.75 mg/ml puromycin (Sigma; P8833) was added to select for transduced cells. Cell lines were eventually
expanded into 10 cm dishes, checked for expression of the appropriate construct by western blot, and frozen down in 1 mL aliquots
containing complete media supplemented with an additional 10% FBS (total of 20%) and 5% DMSO. A549 cells were stably
knocked-down using lentiviruses coding short hairpin RNAs (shRNAs) against Cyclophilin A, B and non-targeting (control) as previ-
ously described (kindly provided by Prof. Ralf Bartenschlager) (Kaul et al., 2009). HAP1 cells edited within the TRIM5 gene were
generated by Horizon Genomics (Vienna) with the RNA guide sequence: CGATTAGGCCGTATGTTCTC.
Antibodies
HA-tagged constructs for western blotting were detected using a 1:5000 dilution of anti-HA-peroxidase antibody (Roche clone 3F10,
#12013819001). HA-tagged constructs for indirect immunofluorescence were detected using anti-HA (Zymed, #71-5500). b-actin
was also detected as a loading control using a 1:10,000 dilution of mouse anti-b-actin (Sigma, A5441). A 1:3,000 dilution of goat
anti-mouse (Dako, #P0447), anti-rabbit (Thermo Scientific, #P0448) or anti-chicken (Millipore, #12-341) horseradish peroxidase-con-
jugated antibody was used as a secondary probe. V5 tagged constructs were probed with anti-mouse V5 (Invitrogen #R960-25).
Blots were developed using the ECL Plus detection reagent (GE Healthcare, #RPN2132). Antibodies to detect viral antigens,
LGTV (NS3 and NS5) (previously described in Taylor et al., 2011), WNV-NS3 (R&D Systems, #AF2907) and dsRNA antibody J2
(English& Scientific Consulting, #10010200). Autophagy and cellular markers were detected using LC3B (Nanotools, #5F10),
GABARAP (Cell Signaling, #E1J4E), Beclin-1 (Novus Biologicals, # 110-53818), ATG5 (Cell Signaling, #2630), p62 (BD Transduction
Laboratories, #610833), cyclophilin A (Enzo, #BML-SA296-0100), cyclophilin B (Thermo Scientific, #PA1-027A), langerin (R&D
Systems, #AF2088) and DC-SIGN (BD Biosciences, #551186).
Immunoprecipitation (IP) and Western Blot Analysis
293 cells were washed three times with PBS (1X) and lysed on ice in RIPA buffer (50 mM Tris-HCl [pH 7.6], 150 mMNaCl, 0.1% SDS,
1% Igepal, and 0.5%Na-deoxycholate) with protease inhibitor cocktail (Roche). For IPs of overexpressed proteins, 2 wells of a 6 well
dish at 1x106 cells/well were used per reaction; for IPs of virus-infected stable TRIM5 HEK293 cells, a 10cm dish of 7x106 cells/dish
was used per reaction; for detection of endogenous TRIM5, HEK293 or HAP1 cells were grown to confluency in 3-4 T150 tissue
culture flasks. Samples were subjected to centrifugation for 10 min at maximum speed to remove cellular debris. Protein G-conju-
gated agarose beads (Roche) or PrecipHen for chicken antibodies (Aves Labs) were used to clear cell lysates at 4C for 3 h. Samples
were centrifuged to remove beads, and 2 mg of antibody analogous to the protein of interest was added to each lysate for 1 h with
rotation at 4C. 50 mL protein G-agarose or PrecipHen beads and were incubated with rotation at 4C overnight. Lysates were
subjected to centrifugation, and beads were washed three times with RIPA buffer prior to elution by incubation at 95C in 13 sample
buffer (62.5 mM TRIS [pH 6.8], 10% glycerol, 15 mM EDTA, 4% 2-ME, 2% SDS, and bromophenol blue). For western blot analysis
HEK293 cell lines were grown to confluency in a 12-well or 6-well dish, collected using a cell scraper, and lysed in RIPA buffer
containing complete protease inhibitor (Roche, #11836170001). After quantification of protein concentration using a Bradford assay,
30 mg of whole cell extract was resolved using a 10%polyacrylamide gel and transferred to a nitrocellulosemembrane. Ubiquitination
assays were performed as previously described (Campbell et al., 2015). Densitometry analysis was performed using ImageJ
software.
Confocal Microscopy
Cells were seeded onto 4 well Lab-Tek II chamber slides overnight. Slides were prepared by washing cells twice with PBS (1X) and
subsequently fixed with paraformaldehyde (4%) for 10 min. For double-stranded RNA (dsRNA) staining, cells were fixed with meth-
anol (100%) for 5 min at 20C. Slides fixed with paraformaldehyde (4%) were further incubated with permeabilization buffer (Triton
X-100 [0.1%], sodium citrate [0.1%]) for 5 min at room temperature and incubated with blocking buffer (PBS[1X], BSA [0.5%] and
goat serum [1%]) for 30 min. Cells were incubated with primary antibody overnight at 4C, washed three times with PBS (1X) and
further incubated with secondary antibody conjugated to Alexa 488, - 594 or 647 (Molecular Probes) for 1 h. Slides were washed
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three time with PBS(1X) and once with ddH20, and mounted onto glass coverslips using Prolong Gold + DAP1 mounting media
(Molecular Probes). Processed slides were imaged using a Zeiss LSM710 confocal microscope and vector profiles analyzed using
Zen software (Carl Zeiss).
Flow cytometry
Cells were harvested at 48 hpi and processed for flow cytometry analysis. Cells were stained with LIVE/DEAD Fixable Aqua DeadCell
Stain Kit (ThermoFisher) and fixed with 4% paraformaldehyde for 20 min at RT. Cells were permeabilized with saponin-containing
buffer and probed with anti-E 11H12 antibody. Data were generated using an LSRII flow cytometer (BD Biosciences) and analyzed
using FlowJo (Tree Star).
RNA Isolation and quantitative RT-PCR
RNAwas isolated from cells using RNeasy kit (QIAGEN) and genomic DNAwas removed with RNase-free DNase (QIAGEN). Reverse
transcription of RNA was performed using Superscript Vilo cDNA Synthesis Kit (Invitrogen) according to manufacturer’s protocol.
TaqMan probes (Table S1) specific for TRIM5, hypoxanthine-guanine phosphoribosyltransferase (HPRT), interferon beta (IFNb),
interlukin 6 (IL6), tumor necrosis factor alpha (TNFa) and C-X-C motif chemokine 10 (CXCL10) were obtained from Applied
Biosystems. Reactions for Real-time RT-PCR were set up in triplicate, cycled and data was collected on the Applied Biosystems
GeneAmp 9500 Sequence detection system. Quantification of relative gene expression was relative to untreated controls with
comparative CT method.
RNA interference
HEK293 and A549 cells were transfected with 15 pmol of siRNA using Lipofectamine RNAiMAX (Life Technologies), refer Table S2.
siRNAs (Dharmacon; SMART pool) were specific against TRIM5 (L-007100), LC3B (L-012846), GABARAP (L-012368), Beclin-1
(L-010552), ATG5 (L-004374) and p62 (L-010230).
Quantification and statistical analysis
All data were evaluated for significance using one-tailed unpaired Student’s t test, or Mann-Whitney U test or one-way/two-way
ANOVA GraphPad Prism 7 software. The number of experimental and technical replicated for statistical analysis is indicated in
each figure legend. Data involving virus titrations were generatedwith values over 2-3 experimental replicates performed in triplicates
and analyzed for significance using Mann-Whitney U test or one-way ANOVA post-test as indicated, in figure legends. Western blots
and experiments involving immunofluorescence were generally performed a minimum of two times, unless quantification was per-
formed in which case the number of experiments is listed in the figure legends. Quantitative image analysis were measured along
vectors drawn in at least 3 fields of cells and validated for significance using two-way ANOVA with Sidak’s or Dunnett’s post-test,
as indicated in figure legends.
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